1 · Remove from regulatory bulk-substance framework
FDA proposed formally excluding semaglutide, tirzepatide from the regulatory bulk-substance framework on a finding of no regulatory need, given that brand-name supply is no longer in shortage.
SeqLine Bio · GLP-1 2026 update
Regulatory update · published 2026-06-05
GLP-1 supply after the FDA's regulated bulk-substance bulks proposal.
On 2026-04-30 the FDA proposed removing GLP-1 medications — tirzepatide — from the regulatory bulk-substance framework. The comment period closes 2026-06-29. Here is what we have read, how it affects qualified B2B buyers, qualified B2B research buyers, and brand owners, and how research-use supply works.
!
Plain-English summary
If finalized, US regulated outsourcing facilities face tighter GLP-1 bulk-substance limits. SeqLine Bio supplies its GLP-1 family as research peptides worldwide; buyers confirm local compliance before import, resale or formulation work.
What the FDA proposed
The 2026-04-30 proposal in three points.
This is not legal advice. Buyers should review primary FDA guidance and confirm with their counsel.
2 · Public comment window
The federal docket comment period is open through 2026-06-29. Stakeholders and manufacturers can submit positions before the rule is finalized.
3 · Shortage resolution
FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025. The regulated bulk-substance bulks removal reflects post-shortage status.
What changes — and what does not
Affected vs unaffected supply tracks.
| regulated outsourcing facilities | Most affected. If finalized, US regulated bulk-substance facilities face tighter limits for semaglutide, tirzepatide or liraglutide from bulk substances. Large-scale low-cost GLP-1 from this channel faces tighter limits. |
|---|---|
| Qualified B2B research buyers | Case-by-case compliance review. Qualified B2B research buyers should separate research-use procurement from any regulated finished-product pathway and confirm local rules before import, resale or formulation work. |
| Qualified B2B buyers and research organizations | Source shift. Qualified B2B buyers and research organizations that relied on regulated bulk-substance-compounded GLP-1 will need to review licensed brand-name channels, qualified B2B research buyer routes, or non-GLP-1 service lines. Non-GLP-1 peptides (BPC-157, Sermorelin, Ipamorelin, NAD+) remain outside the GLP-1 bulk-regulated proposal. |
| worldwide distribution | Not directly affected. Non-US distribution is governed by local regulators. Semaglutide is off-patent in 2026 in several countries including India and China, opening new supply pathways. SeqLine Bio supplies research-grade GLP-1 into these markets. |
| Research labs (US) | Reviewed case-by-case. Research peptide supply for laboratory use is distinct from regulated. We review against current FDA guidance before quoting. |
SeqLine Bio position
How we are responding.
Non-GLP-1 catalog: worldwide supply
Repair, growth-hormone-axis, research, cosmetic and cognitive peptides — BPC-157, TB-500, Sermorelin, Ipamorelin, CJC-1295, GHK-Cu, NAD+, PT-141, MOTS-c — supplied worldwide to qualified B2B and research buyers.
GLP-1 family — research-use, worldwide
Tirzepatide, retatrutide, cagrilintide supplied worldwide as research peptides, for research and private-label brand evaluation. We confirm buyer track before quoting; buyers confirm local regulatory compliance.
FAQ
Questions buyers ask in 2026.
Is compounded GLP-1 going away entirely?
Not entirely. The proposal addresses a regulated bulk-substance pathway. Research-use procurement and non-US markets require separate compliance review; buyers should confirm the applicable rules before import, resale or formulation work.
Will brand-name semaglutide and tirzepatide get cheaper because of patent expiry?
Outside the US, yes — in countries where the semaglutide patent is expiring in 2026, generic-drug makers are entering the market, which generally lowers prices. Inside the US, brand-name pricing is governed by separate dynamics.
Can a brand owner build an OEM GLP-1 line?
SeqLine Bio supplies GLP-1 as research peptides for private-label brand evaluation worldwide, subject to each market's local registration and rules. Large-scale US therapeutic use via regulated bulk-substance bulk substances is restricted under the proposed rule; research and brand-evaluation supply is distinct.
What should qualified B2B buyers plan for?
Confirm the permitted research-use track, destination-market rules and documentation requirements before ordering. Diversify sourcing conversations into non-GLP-1 peptide categories where appropriate. Non-GLP-1 compounds remain a stable supply track for qualified B2B buyers worldwide.
Where can I read the FDA's primary documents?
Search "FDA regulatory bulk-substance framework semaglutide tirzepatide 2026" on fda.gov and the federal docket. Public comments are open through 2026-06-29.
Get specific guidance
Bring us your destination market and we will quote what is supplyable.
We are happy to talk through non-GLP-1 and research-use GLP-1 options for your specific market and buyer track.